Title: Dismantling cognitive-behavioral therapy for chronic insomnia: a protocol for a systematic review and component network meta-analysis

Corresponding author
Yuki Furukawa, MD.
Tokyo Musashino Hospital, 4-11-11, Komone, Itabashi-ku, Tokyo, 173-0037, Japan.
Phone: +81-3-5986-3111
E-mail: furukawa.y.psy@gmail.com

Authors
Yuki Furukawa, MD.
Department of Neuropsychiatry, University of Tokyo Hospital, Tokyo, Japan
Tokyo Musashino Hospital, Tokyo, Japan

Masatsugu Sakata, MA.
Departments of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine / School of Public Health, Kyoto, Japan

Satoshi Funada, MD.
Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine / School of Public Health, Kyoto, Japan

Shino Kikuchi, MD
Kyoto University Graduate School of Medicine, Kyoto, Japan

Toshi A. Furukawa, MD, PhD.
Departments of Health Promotion and Human Behavior and of Clinical Epidemiology, Kyoto University Graduate School of Medicine / School of Public Health, Kyoto, Japan

Edoardo G. Ostinelli, MD.
Department of Psychiatry, University of Oxford, Oxford, UK; Oxford Precision Psychiatry Lab, NIHR Oxford Health Biomedical Research Centre, Oxford, UK; Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK

Orestis Efthimiou, PD.
Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland
Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland

Michael Perlis, PhD.
Behavioral Sleep Medicine Program, Department of Psychiatry, University of Pennsylvania, PA, USA
Chronobiology and Sleep Institute, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
ABSTRACT

Introduction;
Insomnia is highly prevalent and disabling. Clinical practice guidelines recommend cognitive-behavioral therapy for insomnia (CBTI) as the first-line treatment. However, CBTI includes various combinations of many different components and its clinical benefits have been shown as a package, whereas the effect of each component remains unclear. In this study, we will explore the effect of each component of CBTI with the use of component network meta-analysis.

Methods and analysis;
We will include all randomized controlled trials that compared any form of CBTI against another form of CBTI or a control condition in the treatment of adults with chronic insomnia. Concomitant treatments will be allowed as long as they are equally distributed among the arms. We will include both primary and secondary insomnia. The primary outcome of interest in this study is (1) treatment efficacy (remission defined as reaching a satisfactory state at endpoint measured by any validated self-reported scale) at four weeks post-treatment or at its closest time point. Secondary outcomes are (2) acceptability, (3) sleep diary measures and (4) efficacy at long-term follow-up. We will systematically search in PubMed, CENTRAL, PsycINFO and WHO International Clinical Trials Registry Platform. We will assess risk of bias using Cochrane Risk of Bias 2.0 tool. We will conduct component network meta-analysis with the netmeta package in R.

Ethics and dissemination; This study will use published data and does not require ethical approval. Findings will be disseminated in a peer-reviewed journal.

PROSPERO; CRD42022324233.

Keywords
Insomnia; sleep-wake disorder; dismantling study; component network meta-analysis
MAIN TEXT

REVIEW QUESTION
What is the effect of each component of cognitive behavioral therapy for chronic insomnia?

BACKGROUND
Insomnia is highly prevalent and disabling. (Roth et al., 2011) Clinical practice guidelines recommend cognitive-behavioral therapy for insomnia (CBTI) as the first-line treatment. (Edinger et al., 2021; Qaseem et al., 2016) CBTI includes various combinations of many different components and its clinical benefits have been shown as a package, (Straten et al., 2018) whereas the effect of each component remains unclear. Finding the effect of each component will lead to an intervention that may maximize treatment benefit while reducing the number of components, thereby reducing the treatment burden, lowering the cost of CBTI and making it available to more people. Component network meta-analysis (CNMA) is an extension of standard network meta-analysis that can be used to disentangle the treatment effects of different components included in multicomponent interventions. (Rücker et al., 2020b) In this study, we will explore the effect of each component of CBTI with the use of CNMA.

METHODS
We will follow the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guideline extension for NMA. (Hutton et al., 2015) The protocol is prospectively registered in PROSPERO (CRD42022324233).

Data sources
Criteria for considering studies for this review
Study design
We will include all randomized controlled trials that compared any form of CBTI against another form of CBTI or a control condition in the treatment of adults with chronic insomnia. Cluster randomized trials will be included in meta-analyses in accordance with the Cochrane handbook recommendation. (Higgins et al., 2022) If the intra-cluster correlation coefficient is not clearly reported, we assume it to be 0.05. (Lin et al., 2018)
Participants
We will include studies on patients of both genders aged 18 years or older with insomnia either diagnosed according to formal diagnostic criteria (such as the Diagnostic and Statistical Manual of Mental Disorders, the International Classification of Diseases or the International Classification of Sleep Disorders) or judged so by clinical expertise (e.g. presence of significant symptoms). The effect of including studies without a formal diagnosis of insomnia will be tested in a sensitivity analysis. We will include patients with psychiatric or physical comorbidities. (Sateia, 2014) The effect of including such studies will be examined in a sensitivity analysis.
Interventions and controls
We regard CBTI broadly as a psychotherapy involving any one of the following cognitive or behavioral components. Table 1 describes the different components of interest and their definitions. Pharmacological or
psychological co-administration will be allowed as long as it is stated that there were no systematic differences between study arms. CBTI that clearly includes active components focusing on other symptoms, such as depression, anxiety or pain will be excluded when such components are not equally distributed among study arms.

The control conditions of interest will include waiting list, no treatment, attention/psychological placebo control and treatment as usual. In this CNMA study, treatment as usual must include pharmacotherapy; watchful waiting will be classified as attention/psychological placebo even when it is termed ‘treatment as usual’ in some papers. When no treatment, attention/psychological placebo or treatment as usual are used while on the waiting list, such controls will be regarded as waiting list in the NMA but will be decomposed as appropriate in the CNMA. We will include interventions of any duration.

Where multiple arms are reported in a single trial, we will include only the relevant arms that can be described with the components listed in Table 1. We will lump the arms when they share the same components (e.g. same components delivered in 30 min per session against 60 min per session). We will exclude irrelevant arms such as active-drug, pill-placebo, exercise or bright light therapy with equipment. Possible components and their combinations are shown in Table 1 and Table 2. The components and nodes were determined based on previous studies (Edinger et al., 2021; Furukawa et al., 2021) and content expert consensus among co-authors (MS, TAF, MP).

**TABLE 1 List of included components and their definitions**

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Educational components (EDU)</strong></td>
<td></td>
</tr>
<tr>
<td>Sleep hygiene education (se)</td>
<td>General explanation about sleep (e.g., sleep biology, characteristics of healthy sleep, changes in sleep patterns with aging, stress biology, and its impact on sleep) and general recommendations about lifestyle (e.g., diet, exercise, substance use) and environmental factors (e.g., light, noise, temperature) to improve sleep. This may include some elements of other components but those should not be the predominant part of the intervention.</td>
</tr>
<tr>
<td>Sleep diary (sd)</td>
<td>Self-monitoring of important daily sleep-related information using diary.</td>
</tr>
<tr>
<td><strong>Cognitive components (COG)</strong></td>
<td></td>
</tr>
<tr>
<td>Cognitive restructuring (cr)</td>
<td>Skills to identify, challenge and change unhelpful beliefs about sleep that may disturb sleep. This may include behavioral experiments.</td>
</tr>
<tr>
<td>Mindfulness (mi)</td>
<td>A form of meditation emphasizing a nonjudgmental state of heightened or complete awareness of one’s thoughts, emotions, or experiences on a moment-to-moment basis.</td>
</tr>
<tr>
<td>Constructive worry (cw)</td>
<td>Skills not to worry in bed by writing down the worries and their solutions before going to bed.</td>
</tr>
<tr>
<td>Imagery rehearsal (ir)</td>
<td>Skills to identify, challenge and change nightmares that disturb sleep.</td>
</tr>
<tr>
<td><strong>Behavioral components (BEH)</strong></td>
<td></td>
</tr>
<tr>
<td>Intervention</td>
<td>Description</td>
</tr>
<tr>
<td>------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Sleep restriction (sr)</td>
<td>Skills to improve sleep by limiting time in bed. First, time in bed is restricted to the average sleep duration and then it is increased or decreased depending on sleep efficiency.</td>
</tr>
<tr>
<td>Stimulus control (sc)</td>
<td>Skills to re-associate the bed with sleep. Patients are instructed to; wake up at the same time every morning, refrain from daytime napping, go to bed only when sleepy, get out of bed when unable to sleep, and use the bed/bedroom for sleep and sex only.</td>
</tr>
<tr>
<td>Relaxation (re)</td>
<td>Structured exercises designed to reduce somatic tension (eg, abdominal breathing, progressive muscle relaxation, autogenic training) and cognitive arousal (eg, guided imagery training).</td>
</tr>
<tr>
<td>Paradoxical intention (pi)</td>
<td>Exercise to remain awake as long as possible after getting into bed.</td>
</tr>
<tr>
<td><strong>Others</strong></td>
<td></td>
</tr>
<tr>
<td>Waiting component (w)</td>
<td>Participants are aware that they can receive an active treatment after a waiting phase. If patients allocated to the waiting list control condition receive some other potentially therapeutic components, we will consider both the waiting component and the therapeutic components to be present.</td>
</tr>
<tr>
<td>Conventional drug treatment (dt)</td>
<td>Rated positive when conventional drug treatment is present (drug treatment is part of the protocol treatment) or allowed (we will note the percentage of patients on drug).</td>
</tr>
<tr>
<td>Non-specific treatment effect (ns)</td>
<td>Effect of an intervention due to the patients’ belief that they are receiving some form of treatment. Miscellaneous skills not covered in other sections and not expected to have large effect (i.e. quasi-desensitization) are classified as having non-specific treatment effect.</td>
</tr>
<tr>
<td>Self-help, unguided, remote (NA)</td>
<td>Default delivery format is self-help, unguided and remote, as it requires the least human resource.</td>
</tr>
<tr>
<td>Human encouragement (he)</td>
<td>Reminders provided by human beings to proceed with the self-help, remote treatment program via telephone or email. This should not contain any support related to the therapeutic contents. Peer support such as discussion group will be regarded as this component. We will code this component separately from interaction with therapists (in, gp, ff) to see if adding human encouragement to self-help, remote interventions good enough to be effective.</td>
</tr>
<tr>
<td>Therapeutic guidance (tg)</td>
<td>Therapeutic guidance in addition to self-help, remote interventions. This may be provided on a scheduled basis or as-needed basis. Technical support only is not included. We will code this component separately from interaction with therapists (in, gp, ff) to see if adding therapeutic guidance to self-help, remote interventions good enough to be effective.</td>
</tr>
</tbody>
</table>
**Intervention** | **Description**
--- | ---
Individual (in) | Individual interaction with therapists. The combination \((in + ff)\) means individual, face-to-face sessions are held. The combination \((in – ff)\) individual remote sessions, such as via telephone or videoconference.
Group (gp) | Interaction with therapists as a member of a group.
Face-to-face (ff) | Face-to-face interaction with therapists.
Automatic encouragement (ae) | Automated reminders to proceed with the treatment program. This can be added both to the self-help interventions or the interventions including interactions with therapists. This should not contain any support related to the therapeutic contents.

**TABLE 2** Conceptualization of cognitive behavioral therapy for insomnia or control conditions from the component perspective

<table>
<thead>
<tr>
<th>Possible combinations of components</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cognitive behavioral therapy</td>
</tr>
<tr>
<td>Cognitive therapy</td>
</tr>
<tr>
<td>Behavioral therapy</td>
</tr>
<tr>
<td>Psychoeducation</td>
</tr>
<tr>
<td>Waiting list</td>
</tr>
<tr>
<td>Treatment as usual</td>
</tr>
<tr>
<td>Attention or psychological placebo</td>
</tr>
<tr>
<td>No treatment</td>
</tr>
</tbody>
</table>

Components marked with a “+” are required. Components marked with “±” are optional. Components not mentioned cannot be included. Capitalized components (EDU, COG, BEH) mean at least one of the components in that group is required. ae=automatic encouragement. BEH=behavioral components. COG=cognitive components. dt=conventional drug treatment. EDU=educational components. ff=face-to-face. gp=group. he=human encouragement. in=individual. ns=non-specific treatment effect. tg=therapeutic guidance. w=waiting component.

**Search methods for identification of studies**

We will carry out a comprehensive literature search in PubMed, CENTRAL and PsycINFO. We will use a combination of index and free terms of psychological treatments and insomnia with filters (Eady et al., 2008) for randomized clinical trials. We will also search WHO International Clinical Trials Registry Platform. We will impose no date, language or publication status restriction. We will check the reference lists of review articles for additional potentially eligible records.

**TABLE 3** Search strings for PubMed, Cochrane Central Register of Controlled Trials and PsycINFO
<table>
<thead>
<tr>
<th>Database</th>
<th>Search strings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cochrane Central Register of Controlled Trials</td>
<td>([mh Psychotherapy] OR psychotherap* OR &quot;cognitive behavioural therapy&quot; OR &quot;cognitive behavioral therapy&quot; OR &quot;CBT&quot; OR &quot;CBTI&quot; OR &quot;CBT-I&quot; OR &quot;cognitive therapy&quot; OR &quot;behavioural therapy&quot; OR &quot;behavioral therapy&quot; OR &quot;sleep hygiene&quot; OR &quot;sleep education&quot; OR &quot;sleep diary&quot; OR &quot;cognitive restructuring&quot; OR mindfulness OR &quot;constructive worry&quot; OR &quot;imagery rehearsal&quot; OR relaxation OR &quot;sleep restriction&quot; OR &quot;stimulus control&quot; OR &quot;paradoxical intention&quot;) AND  ([mh &quot;sleep wake disorders&quot;] OR insomnia)</td>
</tr>
<tr>
<td>PsycINFO</td>
<td>(exp Psychotherapy/ OR psychotherap*.af. OR &quot;cognitive behavioural therapy&quot;.af. OR &quot;cognitive behavioral therapy&quot;.af. OR &quot;CBT&quot;.af. OR &quot;CBTI&quot;.af. OR &quot;CBT-I&quot;.af. OR &quot;cognitive therapy&quot;.af. OR &quot;behavioural therapy&quot;.af. OR &quot;behavioral therapy&quot;.af. OR &quot;sleep hygiene&quot;.af. OR &quot;sleep education&quot;.af. OR &quot;sleep diary&quot;.af. OR &quot;cognitive restructuring&quot;.af. OR mindfulness.af. OR &quot;constructive worry&quot;.af. OR &quot;imagery rehearsal&quot;.af. OR relaxation.af. OR &quot;sleep restriction&quot;.af. OR &quot;stimulus control&quot;.af. OR &quot;paradoxical intention&quot;.af.) AND (exp &quot;sleep wake disorders&quot;/ OR insomnia.af.) AND (&quot;double-blind&quot; OR &quot;random* assigned&quot; OR control)</td>
</tr>
</tbody>
</table>

**Data collection and analysis**

**Selection of studies**

Two review authors will independently screen titles and abstracts of all the potential studies we identify as a result of the search and code them as ‘retrieve’ or ‘do not retrieve’. We will retrieve the full text study.
reports/publications and two review authors will independently screen the full text and identify studies for inclusion and identify and record reasons for exclusion of the ineligible studies. We will resolve any disagreement through discussion or, if required, we will consult a third reviewer. We will identify publications from the same study so that each study rather than each report is the unit of analysis in the review. We will record the selection process in sufficient detail to complete a PRISMA flow diagram.

Data items
Two review authors will extract independently data from the included studies. Any disagreement will be resolved through discussion, or discussed with a third person if necessary. We will abstract the following information.

1. Characteristics of the studies
Name of the study, year of publication, country, study site (single or multi-center), study design (individually-randomized or cluster-randomized), population characteristics (mean age, number of women, definition of insomnia, number of patients with primary insomnia), intervention (components, delivery format, qualification of therapists [if applicable], duration), outcomes (scale used for the primary outcome)

2. Identification of components
Two independent reviewers will determine the classification of all identified arms and their components according to the definitions in Table 1, based on all available information including the publications, trial registry and inquiry with the original investigators if needed. Any disagreement will be solved by the two reviewers and, where necessary, in consultation with a third member of the review team. We will report the inter-rater agreement in terms of percentage agreement and kappa.

3. Risk of bias
We will use Cochrane Risk of Bias 2.0 tool (RoB2) (Sterne et al., 2019) to assess the risk of bias of the primary outcome. We will report the inter-rater agreement in terms of percentage agreement and kappa.

4. Data to calculate effect sizes
We will extract data to calculate effect sizes (the number of patients randomized to each arm, the number of patients assessed, the number of remitters, the scale used, the mean, standard deviation and the number assessed for continuous outcomes) When only change from baseline to endpoint is reported for continuous outcomes, we will use it instead of endpoint mean.(Costa et al., 2013)

Primary outcome and secondary outcomes
The primary outcome of interest in this study is treatment efficacy at four weeks post-treatment or at its closest time point. Intention-to-treat analysis will be prioritized whenever available. We will use the number of participants randomized as the denominator for dichotomous outcomes. We will use odds ratio for dichotomous outcomes, mean difference for continuous outcomes expressed in minutes and percent.
1. Efficacy: remission defined as reaching a satisfactory state at endpoint measured by any validated self-reported scale (dichotomous)

Secondary outcomes are as follows;
2. Acceptability: dropouts for any reason (dichotomous)
3. Sleep diary measures (continuous)
   3.1. Sleep efficiency (SE, %)
   3.2. Total sleep time (TST, min)
   3.3. Sleep onset latency (SOL, min)
   3.4. Wake after sleep onset (WASO, min)
4. Efficacy at long-term follow-up. (dichotomous, longest follow-up between 3 to 12 months)

**Hierarchy of outcome measures**

For efficacy, we will prioritize the remission using the Insomnia Severity Index (7 or less points at endpoint) (Morin et al., 2011) and its imputed number. If it is not reported, we will use the following scales in this order: the remission using the Functional Outcomes of Sleep Questionnaire-10 (18 or more points at endpoint) (Weaver et al., 2007), and then its imputed number; remission using the Epworth Sleepiness Scale (10 or less points at endpoint) (Johns, 1990), and then its imputed number; remission using the Pittsburgh Sleep Quality Index (5 or less points at baseline) (Cole et al., 2006), and then its imputed number; remission using the Athens Insomnia Scale (5 or less points at endpoint) (Okajima et al., 2020), and then its imputed number; remission using any other validated self-reported scales; remission using sleep diary measures (both SOL and WASO less than 30 minutes at endpoint. When SOL and WASO are reported only separately, we will prioritize WASO. When only SOL is reported, we will use SOL.) (Edinger et al., 2009; American Academy of Sleep Medicine, 2014) and its imputed number.

When any of the measure is reported using another definition of remission than stated above, we will use the definition stated by the authors. When any of the measure is reported only in continuous values, we will impute remission using mean and standard deviation. We will test the validity of this imputation method using studies that report the outcome both in continuous and dichotomous manner. When any of the measure is reported only in standardized mean difference, we will convert it into odds ratio using a validated method. (Chinn, 2000)

**Statistical analysis**

We will perform the analysis in R (latest version, R foundation, Vienna, Austria) (R Core Team, 2020) using netmeta (latest version) package (Rücker et al., 2020a) to conduct component network meta-analysis and meta (latest version) package (Balduzzi et al., 2019) to synthesize the outcomes in placebo arms and to assess the publication bias.

We will first perform a network meta-analysis lumping arms that include both cognitive and behavioral components as “cognitive-behavioral therapy,” those that involve cognitive but not behavioral components as “cognitive therapy” and those that involve behavioral but not cognitive components as “behavioral therapy” to gain a first insight of the relative treatment effects. (Table 2) We will examine the transitivity
assumption by creating a table of important trial and patient characteristics to see if potential effect
modifiers (publication year, proportion of patients with primary insomnia, age) are similarly distributed
among comparisons. We will check the consistency of the network using local and global inconsistency
tests.
Then we will perform component-level network meta-analysis. We will use a model that assumes additivity
of components, i.e. assuming that the effect of combination therapy is the sum of the effects of its
components. Given the expected clinical and methodological heterogeneity of treatment effects among the
studies, we will use the random-effects model.

Certainty of evidence
We will assess the certainty of evidence in network estimates of the primary outcome using
CINeMA. (Nikolakopoulou et al., 2020)

Publication bias
We will assess the presence of small study effects, including publication bias, in the evidence set by
examining asymmetry in the contour-enhanced funnel plots of all active interventions (CBT, CT, BT) vs
control condition (psychoeducation, waiting list, treatment as usual, attention or psychological placebo, no
treatment) using the primary outcome.

Sensitivity analyses
We will conduct sensitivity analyses using the primary outcome.
1. Excluding studies without formal diagnosis of insomnia
2. Excluding studies focusing on patients with comorbidities (both physical and psychological)
3. Excluding studies with overall high dropout rate (20% or more)
4. Excluding studies at high overall risk of bias
5. Using completer-set analysis (dichotomous)

Patient and public involvement
There was no patient or public involvement in the development of this manuscript.

Acknowledgements
The views expressed are those of the authors and not necessarily those of affiliated organizations.

Registration
This protocol is prospectively registered in PROSPERO (CRD42022324233).
This research was prospectively registered (#2022033N1e), Ethical Committee, Faculty of Medicine, The
University of Tokyo.

Changes from the protocol (since the first registration on PROSPERO)
25th May, 2022 (during screening, before data extraction). Although we stated in the protocol that "CBTI
that clearly includes active components focusing on other symptoms, such as depression, anxiety or pain,
will be excluded," in case the same intervention component was included in both arms, we decided to include the trial, as we will be able to see the additional benefit of CBTI.

**Contributions of authors**

Conceiving the protocol: YF, MS, TAF
Designing the protocol: YF, MS, SF, SK, TAF, EGO, OE, MP
Coordinating the protocol: YF
Designing search strategies: YF, EGO
Writing the protocol: YF
Providing general advice on the protocol: TAF, OE, MP
Providing advice on statistical analysis: OE

**Support**

No financial support was used.

** Declarations of interest**

YF has received consultancy fee from Panasonic outside the submitted work.
MS reports personal fees from SONY outside the submitted work.
SF has a research grant from JSPS KAKENHI Grant Number JP 20K18964 and the KDDI Foundation.
SK has a research grant from Mental Health Okamoto Memorial Foundation and Fujiwara Memorial Foundation.
TAF reports grants and personal fees from Mitsubishi-Tanabe, personal fees from SONY, grants and personal fees from Shionogi, outside the submitted work; In addition, TAF has a patent 2020-548587 concerning smartphone CBT apps pending, and intellectual properties for Kokoro-app licensed to Mitsubishi-Tanabe.
EGO has received research and consultancy fees from Angelini Pharma. EGO is supported by the National Institute for Health Research (NIHR) Research Professorship to Professor Andrea Cipriani (grant RP-2017-08-ST2-006), by the National Institute for Health Research (NIHR) Applied Research Collaboration (ARC) Oxford and Thames Valley, by the National Institute for Health Research (NIHR) Oxford cognitive health Clinical Research Facility and by the NIHR Oxford Health Biomedical Research Centre (grant BRC-1215-20005)
OE was supported by the Swiss National Science Foundation (Ambizione grant number 180083)
MP reports no competing interest.
REFERENCE


